NO20032181D0 - Anvendelse av CCI-779 som et antineoplastisk middel - Google Patents

Anvendelse av CCI-779 som et antineoplastisk middel

Info

Publication number: NO20032181D0
Authority: NO; Norway
Prior art keywords: cci; antineoplastic agent; antineoplastic; agent
Prior art date: 2000-11-15

Application number

NO20032181A

Other languages

English (en)

Norwegian (no)

Other versions

NO20032181L (no

Inventor

Gary Dukart

Jr James Joseph Gibbons

Lisa Anne Speicher

Philip Frost

Carolyn Mary Discafani-Marro

Original Assignee

Wyeth Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-11-15

Filing date

2003-05-14

Publication date

2003-05-14

2003-05-14 Application filed by Wyeth Corp filed Critical Wyeth Corp

2003-05-14 Publication of NO20032181L publication Critical patent/NO20032181L/no

2003-05-14 Publication of NO20032181D0 publication Critical patent/NO20032181D0/no

Links

CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 title 1
229940034982 antineoplastic agent Drugs 0.000 title 1
239000002246 antineoplastic agent Substances 0.000 title 1
229960000235 temsirolimus Drugs 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents

Landscapes

Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Urology & Nephrology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

NO20032181A 2000-11-15 2003-05-14 Anvendelse av CCI-779 som et antineoplastisk middel NO20032181D0 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US24907700P	2000-11-15	2000-11-15
PCT/US2001/047324 WO2002040000A2 (en)	2000-11-15	2001-11-13	Use of cci-779 as an antineoplastic agent

Publications (2)

Publication Number	Publication Date
NO20032181L NO20032181L (no)	2003-05-14
NO20032181D0 true NO20032181D0 (no)	2003-05-14

Family

ID=22941961

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20032181A NO20032181D0 (no)	2000-11-15	2003-05-14	Anvendelse av CCI-779 som et antineoplastisk middel

Country Status (27)

Country	Link
US (3)	US20020091137A1 (de)
EP (1)	EP1335725B1 (de)
JP (4)	JP4472251B2 (de)
KR (1)	KR100827942B1 (de)
CN (2)	CN102058588A (de)
AR (1)	AR031341A1 (de)
AT (1)	ATE393629T1 (de)
AU (2)	AU2731302A (de)
BR (1)	BR0115323A (de)
CA (1)	CA2429020C (de)
CY (1)	CY1108109T1 (de)
DE (1)	DE60133831T2 (de)
DK (1)	DK1335725T3 (de)
EA (1)	EA007096B1 (de)
ES (1)	ES2305134T3 (de)
HU (1)	HUP0400521A3 (de)
IL (2)	IL155871A0 (de)
MX (1)	MXPA03004192A (de)
NO (1)	NO20032181D0 (de)
NZ (1)	NZ539668A (de)
PL (1)	PL207061B1 (de)
PT (1)	PT1335725E (de)
SG (1)	SG148031A1 (de)
SI (1)	SI1335725T1 (de)
TW (1)	TWI286074B (de)
WO (1)	WO2002040000A2 (de)
ZA (1)	ZA200304603B (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5362718A (en)	1994-04-18	1994-11-08	American Home Products Corporation	Rapamycin hydroxyesters
TWI286074B (en) *	2000-11-15	2007-09-01	Wyeth Corp	Pharmaceutical composition containing CCI-779 as an antineoplastic agent
EP2269603B1 (de)	2001-02-19	2015-05-20	Novartis AG	Behandlung von Brusttumoren mit einem Rapamycinderivat in Kombination mit Exemestan
TWI296196B (en) *	2001-04-06	2008-05-01	Wyeth Corp	Antineoplastic combinations
US20020198137A1 (en) *	2001-06-01	2002-12-26	Wyeth	Antineoplastic combinations
SG153647A1 (en) *	2001-06-01	2009-07-29	Wyeth Corp	Antineoplastic combinations
EP2407473A3 (de) *	2002-02-01	2012-03-21	ARIAD Pharmaceuticals, Inc	Verfahren zur Herstellung von phosphorhaltigen Verbindungen
JP2005531391A (ja) *	2002-06-27	2005-10-20	微創医療器械（上海）有限公司	薬剤放出ステント
BR0313024A (pt)	2002-07-30	2005-07-12	Wyeth Corp	Formulações parenterais contendo um hidroxiéster de rapamicina
WO2004026280A2 (en) *	2002-09-17	2004-04-01	Wyeth	Granulate formulation of the rapamycin ester cci-779
JP2006514554A (ja)	2002-11-21	2006-05-11	ワイス	腎細胞癌および他の固形腫瘍の診断法
US20050287532A9 (en) *	2003-02-11	2005-12-29	Burczynski Michael E	Methods for monitoring drug activities in vivo
CA2515677A1 (en) *	2003-02-11	2004-08-26	Wyeth	Methods for monitoring drug activities in vivo
US7643943B2 (en)	2003-02-11	2010-01-05	Wyeth Llc	Methods for monitoring drug activities in vivo
UA83484C2 (uk) *	2003-03-05	2008-07-25	Уайт	Спосіб лікування раку грудей комбінацією похідного рапаміцину і інгібітора ароматази - летрозолу, фармацевтична композиція
EP1615640B1 (de) *	2003-04-22	2007-01-24	Wyeth	Antineoplastische zusammensetzungen
EP1618218A2 (de) *	2003-04-29	2006-01-25	Wyeth	Methoden zur prognose und behandlung von soliden tumoren
KR20060052880A (ko) *	2003-07-25	2006-05-19	와이어쓰	동결건조된 ｃｃｉ- 779 제형
AR046194A1 (es) *	2003-11-04	2005-11-30	Mayo Foundation	Metodo de tratamiento del linfoma de celulas del manto
EP1701698B1 (de) *	2004-01-08	2008-01-16	Wyeth a Corporation of the State of Delaware	Direkt komprimierbare pharmazeutische zusammensetzung für die orale verabreichung von cci-779
AR047988A1 (es) *	2004-03-11	2006-03-15	Wyeth Corp	Combinaciones antineoplásicas de cci-779 y rituximab
KR101313702B1 (ko)	2005-02-03	2013-10-04	와이어쓰	제피티니브 및/또는 에를로티니브 내성암 치료용 약제학적 조성물
CN101119709A (zh) *	2005-02-15	2008-02-06	惠氏公司	口服生物有效的cci-779配方
TW200803892A (en) *	2005-11-04	2008-01-16	Wyeth Corp	Antineoplastic combinations with MTOR inhibitor, herceptin, and/or HKI-272
NO346575B1 (no) *	2005-11-21	2022-10-17	Novartis Ag	Anvendelse av 40-O-(2-hydroksyetyl)-rapamycin i behandling av carcinoid eller småøyet celle cancer
KR20080077989A (ko) *	2005-12-20	2008-08-26	와이어쓰	약물의 불순물 조절을 통한 ｃｃｉ-779 제형의 안정성 조절
DE102006011507A1 (de) *	2006-03-14	2007-09-20	Lts Lohmann Therapie-Systeme Ag	Wirkstoffbeladene Nanopartikel auf Basis hydrophiler Proteine
TW200901989A (en) *	2007-04-10	2009-01-16	Wyeth Corp	Anti-tumor activity of CCI-779 in papillary renal cell cancer
US20090076060A1 (en) *	2007-09-17	2009-03-19	Protia, Llc	Deuterium-enriched temsirolimus
US8660003B2 (en) *	2007-10-03	2014-02-25	Genesis Technical Systems Corp.	Dynamic, asymmetric rings
US8022216B2 (en)	2007-10-17	2011-09-20	Wyeth Llc	Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
AU2013205002B2 (en) *	2008-03-21	2016-09-15	The University Of Chicago	Treatment with opioid antagonists and mTOR inhibitors
AU2009225434B2 (en) *	2008-03-21	2014-05-22	The University Of Chicago	Treatment with opioid antagonists and mTOR inhibitors
DK2310011T3 (da)	2008-06-17	2013-10-14	Wyeth Llc	Antineoplastiske kombinationer indeholdende hki-272 og vinorelbin
KR101434009B1 (ko)	2008-08-04	2014-08-25	와이어쓰 엘엘씨	4-아닐리노-3-사이아노퀴놀린과 카페시타빈의 항신생물성 조합물
US9211291B2 (en)	2009-04-06	2015-12-15	Wyeth Llc	Treatment regimen utilizing neratinib for breast cancer
WO2010132233A1 (en) *	2009-05-13	2010-11-18	The Trustees Of The University Of Pennsylvania	Combination antineoplastic therapy
WO2011151704A2 (en) *	2010-06-02	2011-12-08	Fresenius Kabi Oncology Ltd.	Stable pharmaceutical compositions of rapamycin esters
US9745941B2 (en) *	2014-04-29	2017-08-29	Ford Global Technologies, Llc	Tunable starter resistor
CA2992629C (en) *	2015-08-24	2020-06-30	Shanxi Yabao Health Products Co., Ltd.	Use of dihydroxyacetone in preparation of anti-cancer medicaments
CN111110676A (zh) *	2020-03-07	2020-05-08	天津医科大学总医院	阿帕替尼及联合cci-779在制备肺癌药物中的应用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ZA737247B (en)	1972-09-29	1975-04-30	Ayerst Mckenna & Harrison	Rapamycin and process of preparation
US3993749A (en)	1974-04-12	1976-11-23	Ayerst Mckenna And Harrison Ltd.	Rapamycin and process of preparation
US5206018A (en)	1978-11-03	1993-04-27	Ayerst, Mckenna & Harrison, Inc.	Use of rapamycin in treatment of tumors
US4885171A (en)	1978-11-03	1989-12-05	American Home Products Corporation	Use of rapamycin in treatment of certain tumors
BE877700A (fr) *	1978-11-03	1980-01-14	Ayerst Mckenna & Harrison	Compositions pharmaceutiques a base de rapamycine pour le traitement de tumeurs carcinogenes
US4401653A (en)	1981-03-09	1983-08-30	Ayerst, Mckenna & Harrison Inc.	Combination of rapamycin and picibanil for the treatment of tumors
US5100899A (en)	1989-06-06	1992-03-31	Roy Calne	Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof
US5078999A (en)	1991-02-22	1992-01-07	American Home Products Corporation	Method of treating systemic lupus erythematosus
US5080899A (en)	1991-02-22	1992-01-14	American Home Products Corporation	Method of treating pulmonary inflammation
US5321009A (en)	1991-04-03	1994-06-14	American Home Products Corporation	Method of treating diabetes
EP0525960B1 (de)	1991-06-18	1996-03-20	American Home Products Corporation	Verwendung von Rapamycin zur Behandlung von T-Zellen Lymphom/Leukämie bei Erwachsenen
IL102414A (en)	1991-07-25	1996-08-04	Univ Louisville Res Found	Medicinal preparations for the treatment of ocular inflammation, containing rapamycin
US5286731A (en)	1991-09-17	1994-02-15	American Home Products Corporation	Method of treating immunoinflammatory bowel disease
US5286730A (en)	1991-09-17	1994-02-15	American Home Products Corporation	Method of treating immunoinflammatory disease
US5516781A (en)	1992-01-09	1996-05-14	American Home Products Corporation	Method of treating restenosis with rapamycin
US5288711A (en)	1992-04-28	1994-02-22	American Home Products Corporation	Method of treating hyperproliferative vascular disease
ZA935112B (en)	1992-07-17	1994-02-08	Smithkline Beecham Corp	Rapamycin derivatives
US5362718A (en) *	1994-04-18	1994-11-08	American Home Products Corporation	Rapamycin hydroxyesters
US5561138A (en)	1994-12-13	1996-10-01	American Home Products Corporation	Method of treating anemia
US5496832A (en)	1995-03-09	1996-03-05	American Home Products Corporation	Method of treating cardiac inflammatory disease
MXPA03001245A (es)	2000-08-11	2003-05-27	Wyeth Corp	Metodo para el tratamiento del carcionma positivo para receptores de estrogeno.
TWI286074B (en) *	2000-11-15	2007-09-01	Wyeth Corp	Pharmaceutical composition containing CCI-779 as an antineoplastic agent
TWI233359B (en)	2001-04-06	2005-06-01	Wyeth Corp	Pharmaceutical composition for treating neoplasm
TWI296196B (en)	2001-04-06	2008-05-01	Wyeth Corp	Antineoplastic combinations
UA77200C2 (en)	2001-08-07	2006-11-15	Wyeth Corp	Antineoplastic combination of cci-779 and bkb-569

2001
- 2001-11-05 TW TW090127415A patent/TWI286074B/zh not_active IP Right Cessation
- 2001-11-13 JP JP2002542375A patent/JP4472251B2/ja not_active Expired - Lifetime
- 2001-11-13 US US10/010,584 patent/US20020091137A1/en not_active Abandoned
- 2001-11-13 AU AU2731302A patent/AU2731302A/xx active Pending
- 2001-11-13 CA CA002429020A patent/CA2429020C/en not_active Expired - Lifetime
- 2001-11-13 PT PT01996175T patent/PT1335725E/pt unknown
- 2001-11-13 SI SI200130829T patent/SI1335725T1/sl unknown
- 2001-11-13 DE DE60133831T patent/DE60133831T2/de not_active Expired - Lifetime
- 2001-11-13 EA EA200300566A patent/EA007096B1/ru not_active IP Right Cessation
- 2001-11-13 ES ES01996175T patent/ES2305134T3/es not_active Expired - Lifetime
- 2001-11-13 WO PCT/US2001/047324 patent/WO2002040000A2/en not_active Ceased
- 2001-11-13 IL IL15587101A patent/IL155871A0/xx unknown
- 2001-11-13 KR KR1020037006542A patent/KR100827942B1/ko not_active Expired - Lifetime
- 2001-11-13 MX MXPA03004192A patent/MXPA03004192A/es active IP Right Grant
- 2001-11-13 CN CN2010101653331A patent/CN102058588A/zh active Pending
- 2001-11-13 DK DK01996175T patent/DK1335725T3/da active
- 2001-11-13 EP EP01996175A patent/EP1335725B1/de not_active Expired - Lifetime
- 2001-11-13 AT AT01996175T patent/ATE393629T1/de not_active IP Right Cessation
- 2001-11-13 PL PL362740A patent/PL207061B1/pl unknown
- 2001-11-13 CN CNA018189261A patent/CN1678312A/zh active Pending
- 2001-11-13 HU HU0400521A patent/HUP0400521A3/hu unknown
- 2001-11-13 SG SG200505237-8A patent/SG148031A1/en unknown
- 2001-11-13 BR BR0115323-4A patent/BR0115323A/pt not_active Application Discontinuation
- 2001-11-13 NZ NZ539668A patent/NZ539668A/en unknown
- 2001-11-14 AR ARP010105310A patent/AR031341A1/es unknown
2003
- 2003-02-26 US US10/374,644 patent/US7189735B2/en not_active Expired - Lifetime
- 2003-05-12 IL IL155871A patent/IL155871A/en active IP Right Grant
- 2003-05-14 NO NO20032181A patent/NO20032181D0/no not_active Application Discontinuation
- 2003-06-12 ZA ZA200304603A patent/ZA200304603B/en unknown
2007
- 2007-02-01 US US11/701,109 patent/US7781446B2/en not_active Expired - Fee Related
- 2007-03-27 AU AU2007201324A patent/AU2007201324B2/en not_active Expired
2008
- 2008-06-02 CY CY20081100573T patent/CY1108109T1/el unknown
2009
- 2009-09-18 JP JP2009216883A patent/JP2010018620A/ja active Pending
2014
- 2014-01-15 JP JP2014005231A patent/JP2014088430A/ja not_active Withdrawn
2015
- 2015-12-10 JP JP2015241449A patent/JP2016094444A/ja not_active Withdrawn

Also Published As

Publication number	Publication date
CN102058588A (zh)	2011-05-18
IL155871A0 (en)	2003-12-23
US20030153593A1 (en)	2003-08-14
TWI286074B (en)	2007-09-01
EA007096B1 (ru)	2006-06-30
AU2007201324B2 (en)	2010-11-18
DE60133831D1 (de)	2008-06-12
NO20032181L (no)	2003-05-14
HUP0400521A2 (hu)	2004-06-28
WO2002040000A2 (en)	2002-05-23
US7781446B2 (en)	2010-08-24
DE60133831T2 (de)	2009-05-20
SG148031A1 (en)	2008-12-31
AU2007201324A1 (en)	2007-04-19
IL155871A (en)	2012-03-29
JP2004517065A (ja)	2004-06-10
KR100827942B1 (ko)	2008-05-13
ZA200304603B (en)	2004-09-13
US20020091137A1 (en)	2002-07-11
NZ539668A (en)	2007-06-29
EA200300566A1 (ru)	2003-10-30
WO2002040000A3 (en)	2002-09-06
MXPA03004192A (es)	2003-09-22
CA2429020A1 (en)	2002-05-23
US20070142425A1 (en)	2007-06-21
JP2014088430A (ja)	2014-05-15
HK1058008A1 (en)	2004-04-30
CN1678312A (zh)	2005-10-05
SI1335725T1 (sl)	2008-08-31
ES2305134T3 (es)	2008-11-01
CY1108109T1 (el)	2014-02-12
CA2429020C (en)	2009-05-26
PT1335725E (pt)	2008-06-19
AU2731302A (en)	2002-05-27
PL207061B1 (pl)	2010-10-29
US7189735B2 (en)	2007-03-13
JP2010018620A (ja)	2010-01-28
DK1335725T3 (da)	2008-06-30
KR20040029309A (ko)	2004-04-06
ATE393629T1 (de)	2008-05-15
PL362740A1 (en)	2004-11-02
JP4472251B2 (ja)	2010-06-02
EP1335725A2 (de)	2003-08-20
EP1335725B1 (de)	2008-04-30
BR0115323A (pt)	2004-02-17
AR031341A1 (es)	2003-09-17
JP2016094444A (ja)	2016-05-26
HUP0400521A3 (en)	2007-05-29

Publication	Publication Date	Title
NO20032181D0 (no)	2003-05-14	Anvendelse av CCI-779 som et antineoplastisk middel
NO20032840D0 (no)	2003-06-20	Heterocykloindazol- og azaindazol-forbindelser som 5- hydroksytryptamin-6-ligander
NL300343I1 (nl)	2008-06-02	6-alfa, 9-alfa-difluor-17-alfa-(2-furanylcarboxyl)oxy-11-beta-hydroxy-16-alfa-methyl-3-oxo-androst-1, 4-dieen-17-carbothionzuur-s-fluormethylester alseen ontstekingremmend middel
NO20015855L (no)	2002-01-30	Ny anvendelse av forbindelser som antibakterielle midler
NO20030929L (no)	2003-04-30	Guanidinobenzamider som MC4-R agonister
NO20026037L (no)	2003-02-06	Sötvareprodukt som inneholder aktive bestanddeler
AR028567A1 (es)	2003-05-14	Nuevos derivados de fenil-propargileter
DK1250047T3 (da)	2005-05-30	Herbicidt middel
NO20030138L (no)	2003-01-10	Lipidrikt plakkinnkapslende middel
PT1399127E (pt)	2005-07-29	Formulacoes de olopatadina para administracao topica
AR028596A1 (es)	2003-05-14	Nuevos derivados de fenilglicina
NO20042112L (no)	2004-07-09	Anvendelse av glycosider av mono- og diacylglycerol som anti-inflammatoriske midler.
NO20012636D0 (no)	2001-05-29	Kontrollert frigivelsesformulering som omfatter GNRH-II
NO20032531D0 (no)	2003-06-04	Tetralon-derivater som antitumormidler
NO20041316L (no)	2004-03-30	Tiofen- og tiazoisulfonamider som antineoplastiske midler
DK1456206T3 (da)	2008-09-08	Azaindolylalkylaminderivater som 5-hydroxytryptamin-6-ligander
DK1073416T3 (da)	2009-03-09	Anvendelse af NO som anti-inflammatorisk middel
DK1455779T3 (da)	2006-10-30	Indolylalkylaminderivater som 5-hydroxytryptamin-6-ligander
NO20032841D0 (no)	2003-06-20	Heterocykloindol- eller azaindol-forbindelser som 5- hydroksytryptamin-6-ligander
DK1144431T3 (da)	2006-05-08	16-Hydroxyestratriener som selektivt aktive estrogener
NO20021959D0 (no)	2002-04-25	Tetrahydrotiopyranftalazinon-derivater som PDE4-inhibitorer
NO20043084L (no)	2004-07-16	3-fenyl-2-arylalkyltiopropionsyre derivater som selektive agnoister av PPAR-ALPHA
PT1268482E (pt)	2004-01-30	Piranoindois para o tratamento de glaucoma
DE60220799D1 (de)	2007-08-02	Hypoglykämisches mittel
AR028398A1 (es)	2003-05-07	Ciclipostinas, procedimiento para su preparacion, y utilizacion de las mismas

Legal Events

Date	Code	Title	Description
2011-05-30	FC2A	Withdrawal, rejection or dismissal of laid open patent application